02nd week of 2012 patent applcation highlights part 35 |
Patent application number | Title | Published |
20120009198 | Compositions and Methods for Modulating Immune Response - The present invention relates to a method for modulating immune response in a subject, which comprises administering to the subject an effective amount of a composition comprising a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using | 2012-01-12 |
20120009199 | ANTIBODY FORMULATIONS - The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation. | 2012-01-12 |
20120009200 | FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR-3) INHIBITORS AND METHODS OF TREATMENT - The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer. | 2012-01-12 |
20120009201 | RENAL CELL CARCINOMA BIOMARKERS - Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker. | 2012-01-12 |
20120009202 | TARGET HOST FACTORS FOR TREATING VIRAL INFECTION - A method of reducing virus-mediated cytotoxicity comprising contacting virus-infected cells with an effective amount of at least one inhibitor of ABI2, ARRDC3, BAD, BRCA1, C17orf85, C1orf71, C6orf162, CCNJL, CFL1, GON4L, HCG 1986447, HIST1H2AB, HPS4, LHX8, RPS25, RPL23, RPL32, LOC730139, LRRC39, MALT1, MX1, MERTK, MX2, NRG1, OR52A1, PLEKHH1, PTPN13, PTPRJ, RLN1, RNF19A, SH3BP4, SLC7A14, ST8SIA3, STX3, TMC6, TMTC4, TNFSF12-TNFSF13, TNFSF13, TTN, UBXN7, USP47, WNK2, YPEL2, ZNF251 and/or SCG2. | 2012-01-12 |
20120009203 | Depletion of cancer stem cells - Compositions and methods are provided for killing of cancer stem cells, and for the transplantation of pluripotent stem cells and differentiated cells derived therefrom. | 2012-01-12 |
20120009204 | Treatment of Metastatic Breast Cancer - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody. | 2012-01-12 |
20120009205 | Modified Fc Molecules - Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed. | 2012-01-12 |
20120009206 | NOVEL DOUBLE-STRANDED RIBONUCLEIC ACIDS WITH RUGGED PHYSICO-CHEMICAL STRUCTURE AND HIGHLY SPECIFIC BIOLOGIC ACTIVITY - A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C | 2012-01-12 |
20120009207 | Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells - The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases. | 2012-01-12 |
20120009208 | USE OF MEMBRANE ATTACK COMPLEX (MAC) AND IMMUNE COMPLEXES (ICs) TO ACTIVATE T-CELLS AND THE GENERATION OF REGULATORY T CELLS - The invention describes the use of antigen-antibody complexes also known in the field as immune complexes to activate T cells and their potential to differentiate them into effector T cells for use in therapy. It also describes a process to achieve benefit from disrupting this T cell activation mediated by antigen-antibody complex and sublytic MAC of the complement system. | 2012-01-12 |
20120009209 | ENRICHMENT AND PURIFICATION OF INFECTIOUS PRION PROTEINS - Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein. | 2012-01-12 |
20120009210 | HYPALLERGENIC MOSAIC ANTIGENS AND METHODS OF MAKING SAME - Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order. | 2012-01-12 |
20120009211 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 2012-01-12 |
20120009212 | CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE - Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in order to form a two-stranded antigen suitable for immunization of a subject. | 2012-01-12 |
20120009213 | Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 2012-01-12 |
20120009214 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 2012-01-12 |
20120009215 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 2012-01-12 |
20120009216 | EARLY DETECTION OF FLAVIVIRUSES USING THE NS1 GLYCOPROTEIN - The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal or monoclonal antibodies pre-selected for their high affinity for said NS1 protein hexameric in shape. | 2012-01-12 |
20120009217 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 2012-01-12 |
20120009218 | Attenuated Gram Negative Bacteria - Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed. | 2012-01-12 |
20120009219 | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN SEQUENCES - The invention relates to improved methods of producing and recovering | 2012-01-12 |
20120009220 | Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen - Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 2012-01-12 |
20120009221 | TRANSFECTION OF BLOOD CELLS WITH MRNA FOR IMMUNE STIMULATION AND GENE THERAPY - The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy. | 2012-01-12 |
20120009222 | MODULATION OF THE IMMUNE RESPONSE - The present invention provides lipidoids that can be used to modulate the immune response in a subject. Lipidoids are prepared by the conjugate addition of an amine to an acrylate to acrylamide. The lipidoids form complexes or particles with an immunostimulatory polynucleotide, which are then administerd to a subject. Such compositions have been found to stimulate the production of cytokines and increase both humoral and cell-mediate immune response. The invention also provides pharmaceuti-cal compositions thereof and methods for using the same. | 2012-01-12 |
20120009223 | COLLAGEN-BASED HYDROGELS LOADED WITH ZnO QDs/pDNA COMPLEXES AS CORNEAL SUBSTITUES - This invention relates to a method of fabricating collagen-based hydrogels loaded with ZnO QDs/pDNA complexes as corneal substitutes. Polycation-modified ZnO Quantum Dots were encapsulated into IPN hydrogels by the adsorption effect of freeze-dried hydrogels. The weight ratio of substitutes and ZnO QDs complex is approximately 425:1. And the weight ratio of ZnO QDs/pDNA is 25:1. This kind of corneal substitutes possess favorable biocompatibility. It is able to induce and promote the regeneration of the cornea and it will degrade along with the regeneration of the cornea. The incorporation of the MPDSAH can enhance the stability of corneal substitutes under the existence of collagenase. ZnO QDs used in this invention can condense DNA effectively and ferry DNA into cells successfully. In the process of transfection, the location and distribution of DNA/vector can be tracked by fluorescence in real time. What's more, the convenience of preparation, long term storage and transportation offers a general method to fabricate a promising corneal substitute. | 2012-01-12 |
20120009224 | PARTICULATE CARTILAGE TREATMENT COMPOSITION - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 2012-01-12 |
20120009225 | Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration - Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 2012-01-12 |
20120009226 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein is an impurity of laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide (deschloro laquinimod impurity), and process for preparation and isolation thereof. Provided further herein is a highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity. | 2012-01-12 |
20120009227 | ACTIVE COATING OF PHARMACEUTICAL DOSAGE FORMS - The present invention describes in an embodiment a coating composition which contains in a film coating an active pharmaceutical ingredient, which is defined by a low water solubility of about 10 mg/ml or lower as measured in water at 20° C. at about pH 7, or which is defined by presenting a dispersed state when placed in water at 20° C. at about pH 7, and a co-polymer of polyvinyl alcohol with polyethylene glycol. Preferably the active pharmaceutical ingredient has been applied dispersed in an aqueous coating vehicle onto a core which optionally comprises a same or different active pharmaceutical ingredient. The present invention also describes a process for the preparation of a pharmaceutical single unit dosage form, wherein the process comprised the steps of providing a core of the single unit dosage form, optionally providing one or more subcoating layer(s) on the core, subjecting the core to film coating using a composition comprising an aqueous coating vehicle, a co-polymer of polyvinyl alcohol with polyethylene glycol and at least one active pharmaceutical ingredient dispersed in the aqueous coating vehicle, wherein said co-polymer amounts for at least 7.0 wt. %, preferably at least 9.4 wt. % of said composition and the weight ratio of said co-polymer to said active pharmaceutical ingredient is at least 1:1 to 5:1. Other process embodiments are also described. High drug loads, uniformity of drug load, and fast dissolution rates of active pharmaceutical ingredient from film coatings of pharmaceutical single unit dosage forms can be achieved according to the present invention. | 2012-01-12 |
20120009228 | Prebiotic Compositions for use with Probiotics to Increase Probiotic Growth Rate and Activity - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 2012-01-12 |
20120009229 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 2012-01-12 |
20120009230 | MALLEABLE IMPLANTS CONTAINING DEMINERALIZED BONE MATRIX - Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids can include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising one or more polysaccharides. Also described are methods for making and using such medical compositions. | 2012-01-12 |
20120009231 | APPARATUS AND METHOD FOR DEPOSITION OF FUNCTIONAL COATINGS - A method for deposition of functional coatings comprises igniting a non-thermal equilibrium plasma within an ambient pressure plasma chamber having a gas supply inlet and a plasma outlet; and providing a substrate to be coated adjacent to the plasma outlet. A gas phase pre-cursor monomer is provided to the plasma chamber through the gas inlet. A specific energy is coupled into the plasma during the flow of the pre-cursor through the chamber sufficient to disassociate at least the weakest intra-molecular bond required to allow polymerisation of the pre-cursor when deposited on a surface of the substrate adjacent the plasma outlet, the coupled specific energy not exceeding a specific energy required break intra-molecular bonds required for the functionality of the monomer molecule. | 2012-01-12 |
20120009232 | ANTIPERSPIRANT COMPOSITIONS AND METHODS FOR MANUFACTURING ANTIPERSPIRANT COMPOSITIONS - Antiperspirant compositions and methods for fabricating antiperspirant compositions are provided. In accordance with an exemplary embodiment, an antiperspirant composition comprises an active antiperspirant compound, stearyl alcohol, and a 14/16 chain fatty alcohol present in an amount of from about 0.5 to about 6 weight percent of the antiperspirant composition. | 2012-01-12 |
20120009233 | Skin Care Compositions and Treatments - The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue. | 2012-01-12 |
20120009234 | COSMETICS - It is provided cosmetics to prevent to come off and keep long. The cosmetic comprises specific polyurethane particles with a cosmetic base. The specific polyurethane particle consists of a body of the polyurethane particle and hydrophilic fine silica powders existing on the body. The body is obtained by three-dimensionally polymerizing an isocyanate-terminated urethane prepolymer with trifunctional or more functional amines. The isocyanate-terminated urethane prepolymer is obtained by reacting polyisocyanates and polyols including a poly(tetramethylene ether)glycol. The polyurethane particles are obtained by spray-drying a mixed aqueous dispersion in which the hydrophilic fine silica powders and the polyurethane spheres are dispersed in water. | 2012-01-12 |
20120009235 | STABILIZED PEELING CAPSULE - The invention comprises a topically applicable capsule that can be spread by rubbing on the skin, comprising an emulsion-based casing material and a filler material containing a preparation having an abrasive action surrounded by a coating that is applied by a spray technique or dipping bath. | 2012-01-12 |
20120009236 | Formable Aquatic Coverings For Preventing Biofouling - The instant invention describes an anti-biofouling structure for placement onto structures or surfaces that are exposed to aquatic environments. Embedded within the anti-biofouling structure are agents that can diffuse out of the structure and prevent the formation and/or accumulation of plant and animal species build-up that creates biofouling. The instant invention also describes a system for preventing biofouling of an object stored in an aquatic environment which includes the anti-biofouling structure, and a protective cover element constructed and arranged to fit various structures, such as boat propellers. | 2012-01-12 |
20120009237 | WOUND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS - Disclosed are keratin preparations for use in medical applications. Methods of treating wounds are provided, wherein keratin preparations are applied to the wound in a treatment effective amount. Methods of treating burn wounds are also provided. Surgical or paramedic aids are provided, comprising a substrate with keratin preparations provided thereon. Kits comprising keratin derivatives packaged in sterile form are also provided. | 2012-01-12 |
20120009238 | METHOD FOR TREATMENT OF CROP WITH AN ENCAPSULATED PESTICIDE - The present invention is related to a method for the pesticidal treatment of crops which have a final growth height of at least 140 cm, comprising the treatment with an encapsulated pesticide at a growth height of the crop of up to 120 cm. The invention further relates to a composition comprising an encapsulated pesticide and a composition comprising a mixture of an encapsulated pesticide and a non-encapsulated, additional pesticide. Finally, the invention also relates to a use of an encapsulated pesticide for the pesticidal treatment of crop which has a final growth height of at least 140 cm at a growth height of the crop of less than 120 cm. | 2012-01-12 |
20120009239 | Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 2012-01-12 |
20120009240 | Films for Delivery of a Therapeutic Agent - The present disclosure relates to self-supporting films for delivery of a therapeutic agent containing at least one hydrophobic polymer and at least one therapeutic agent. Methods of forming the multilayer films are also disclosed. | 2012-01-12 |
20120009241 | SKIN WOUND DRESSING AND PREPARING METHOD THEREOF - A skin wound dressing is disclosed. The skin wound dressing comprises Tremella polysaccharide and alginate and is used to cover on a skin wound to accelerate wound healing. The Tremella polysaccharide is isolated from a hot water extract of | 2012-01-12 |
20120009242 | BLOOD COAGULATION INDUCING POLYMER HYDROGEL - The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated. | 2012-01-12 |
20120009243 | LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF - The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention. | 2012-01-12 |
20120009244 | NEUROD1 GENE EXPRESSION IN NON-ENDOCRINE PANCREATIC EPITHELIAL CELLS (NEPECs) - The introduction of the human NeuroD1 gene into human non-endocrine pancreatic epithelial cells (NEPECs) for producing insulin producing cells in vitro is described herein. Cytokeratin19 (CK19) positive NEPECs were transfected with plasmids encoding human NeuroD1 gene under human CK19 promoter. On characterization following the induction it was found that NEPEC+ND strongly expressed NeuroD1 and insulin mRNA. The ratio of NeuroD1 and human insulin positive cells in NEPEC+ND was significantly higher than NEPEC. Human insulin and C-peptide levels in culture media in NEPEC+ND were significantly higher than NEPEC. The findings demonstrate that human NeuroD1 under control of the CK19 promoter induces the differentiation of CK19 positive NEPECs into insulin producing cells. | 2012-01-12 |
20120009245 | Administration of Growth Factors for the Treatment of CNS Disorders - A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described. | 2012-01-12 |
20120009246 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS - Phospholipid-analogous compounds of the general formula (I) | 2012-01-12 |
20120009247 | PHOSPHOLIPID DRUG ANALOGS - Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: | 2012-01-12 |
20120009248 | Preservation of Bioactive Materials By Spray Drying - This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials. | 2012-01-12 |
20120009249 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS - This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain. | 2012-01-12 |
20120009250 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS - This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action. | 2012-01-12 |
20120009251 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 2012-01-12 |
20120009252 | LIPOSOMAL FORMULATIONS OF ANTHRACYCLINE AGENTS AND CYTIDINE ANALOGS - Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent. | 2012-01-12 |
20120009253 | PREPARATIONS FOR THE APPLICATION OF ANTI-INFLAMMATORY, ESPECIALLY ANTISEPTIC AGENTS AND/OR AGENTS PROMOTING THE HEALING OF WOUNDS OF THE LOWER RESPIRATORY TRACT - Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents. | 2012-01-12 |
20120009254 | Respiratory Syncytial Virus Antigenic Compositions and Methods - Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response. | 2012-01-12 |
20120009255 | METHODS OF TREATING INFECTIOUS DISEASES - The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C | 2012-01-12 |
20120009256 | Treatment Including Prebiotic Composition for use with Probiotics - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 2012-01-12 |
20120009257 | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren - The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of valsartan in the presence of aliskiren is overcome by the use of disintegrants. | 2012-01-12 |
20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 2012-01-12 |
20120009259 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 2012-01-12 |
20120009260 | NANOPARTICLE FILM DELIVERY SYSTEMS - A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function. | 2012-01-12 |
20120009261 | NOVEL GASTRO-RETENTIVE DOSAGE FORMS - A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for formulating for once daily or twice daily administration. Further provided is a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The opioid is either in slow release form or in immediate release form. | 2012-01-12 |
20120009262 | MEDICAL APPARATUS AND METHOD FOR PRODUCING SAME - A medical device that includes at least one antibiotic in a macromolecular substance that swells upon contact with a solvent. Also, a method for preparing an antibiotic-containing medical device that involves contacting a medical device having at least a portion of the surface formed from a swellable macromolecular substance, with a solvent that swells the macromolecular substance, contacting the swollen macromolecular substance with at least one antibiotic, and removing the solvent from the swollen macromolecular substance. | 2012-01-12 |
20120009263 | GRANULAR DELIVERY SYSTEM - A granular delivery system and a method of preparing the same by creating a melt emulsion having a continuous phase and a dispersed active, wherein the continuous phase includes trehalose and a hydrogenated starch hydrolysate having number average degree of polymerization, DPn, of between 5 and 100, or a number average molecular weight, Mn of between 800 and 16000 Da, forcing the melt emulsion through an die or orifice to form an extrudate, cooling and granulating the extrudate to form granules of the delivery system and optionally drying the granules. | 2012-01-12 |
20120009264 | DRUG CARRIER FOR TREATING OF GASTROINTESTINAL ULCER - A drug carrier for treating of gastrointestinal ulcer comprises a microspheroid having a substrate and a plurality of particles distributed over and covered by the substrate, wherein the substrate is alginate and the plurality of particles is a drug for treating of gastrointestinal ulcer; and a coat covering up the surface of the microspheroid, which contains chitosan. | 2012-01-12 |
20120009265 | DRUG CARRIER - A drug carrier comprises a substance, a paramagnetic particle, a rod-shaped light-absorbing particle and a drug. The paramagnetic particle, the drug and the rod-shaped light-absorbing particle absorbing light and generating heat are provided in the substance. | 2012-01-12 |
20120009266 | COMPOSITION COMPRISING OCAPERIDONE - The present invention relates to a composition comprising ocaperidone as an active substance and an effective amount of water-soluble polymers to increase solubility of ocaperidone. The present invention further relates to a therapeutic system for ocaperidone with a compartment for the drug formulation comprising said composition, and to a process for the preparation thereof as well as to the therapeutic use of said composition as antipsychotic drug. The present invention also relates to the solubilisation of ocaperidone in an aqueous medium with the aid of water soluble swellable polymers. | 2012-01-12 |
20120009267 | NANOPARTICLE COMPOSITIONS AND METHODS FOR IMPROVED ORAL DELIVERY OF ACTIVE AGENTS - Nanoparticles, compositions, and methods for the improved uptake of active agents are disclosed herein. The compositions contain a monodisperse population of nanoparticles, preferably including an active agent, where the nanoparticles are formed from a polymeric material possessing specified bioadhesion characteristics. Following enteral administration, preferably oral administration, the nanoparticles exhibit total intestinal uptakes of greater than 20%, preferably greater than 45%, more preferably greater than 65%. When compared to uptake of the same composition in the absence of the bioadhesive polymeric material, the nanoparticles have significantly increased uptake with intestinal uptake of the increased by more than 100%, preferably even greater than 500%. Further disclosed herein is a method of producing multi-walled nanoparticles, as well as methods of using thereof. Multi-walled particles prepared using the method disclosed herein are useful for controlling the release of active agents. | 2012-01-12 |
20120009268 | Modified Virus Vectors and Methods of Making and Using the Same - The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 2012-01-12 |
20120009269 | RANGE OF ASEPTICALLY PRODUCED INFANT FOODS HAVING LOW CONCENTRATIONS OF UNDESIRED BY-PRODUCTS AND METHODS FOR MAKING THE SAME - A range of infant food products wherein each product in the range includes minimal levels of undesired by-products produced during processing as indicated by less than about 15 micrograms furan per kg food product. | 2012-01-12 |
20120009270 | TREATMENT METHODS USING A PARTICULATE CARTILAGE SYSTEM - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 2012-01-12 |
20120009271 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION - Stem cells are exposed to disease condition (the OGD stroke model), that mimics the target disease (stroke), allowing the stem cells to exert better neuroprotective effects. Thus, the present technology demonstrates a disease-tailored stem cell therapy. The present invention discloses that the administration of a therapeutically effective amount of amnion derived stem cells concomitantly with a therapeutically effective dose of melatonin provides additive/synergistic neuroprotective effects. Moreover, the present invention offers an equally robust technology employing a receptor-regulated mechanism, whereby stem cells can be enhanced (melatonin treatment) over their basal level (lack of melatonin treatment), facilitating a regulation of stem cells. | 2012-01-12 |
20120009272 | Compositions and methods for creating an air release mechanism to maintain skin health - A topical composition and method for the treatment of the symptoms of diaper rashes and skin irritations by creating an air circulating mechanism comprising a) bicarbonate of soda; b) corn starch; c) citric acid; d)a carrier oil; e) a pharmaceutically acceptable moisturizer; f) fragrance oil; and g) food grade coloring. The carrier oil is selected from the group consisting of almond oil, coconut oil, sunflower oil, apricot kernel oil, avocado oil, canola oil, evening primrose oil, grapeseed oil, hazelnut oil, jojoba oil, macadamia oil, olive oil, sesame oil, rosehip seed oil, and mixtures thereof. The pharmaceutically acceptable moisturizer is either purified water or witch hazel. In its preferred embodiments, the composition can result in a loose powder for application directly to the diapered skin, an effervescent bath tablet, and as an additive to the bodyfacing layer of a diaper. | 2012-01-12 |
20120009273 | KIT OF PHARMACEUTICAL FORMULATIONS CHARACTERIZED BY THE PRESENCE OF MOLECULAR OXYGEN - An array of pharmaceutical formulations characterized by the presence of molecular oxygen comprising four elements which, in combination, furnish benefits for the health of patients with HIV AIDS: (i) weight increase of the patient; (ii) increase of appetite; (iii) reduction of diarrhea; (iv) reduction of the wasting syndrome; (v) increase of stability of mood; (vi) increase of muscular mass. (vii) decrease of opportunistic diseases, in particular infections caused by Candida, herpes virus, cytomegalovirus, Kaposi's sarcoma; (viii) prolongation of the period wherein the patient does not require to take antiretrovirals; (ix) increase of acceptance of pharmacological treatment; x. reduction of gastritis, nausea or vomiting, headache; (xi) reduction of cases with anemia or thrombocytopenia; and (xii) a change in the phase of the disease in the patient. | 2012-01-12 |
20120009274 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER - The present invention relates to the use of hydrazone compounds and copper for controlling the growth of fungi. | 2012-01-12 |
20120009275 | In-situ forming hydrogel wound dressings containing antimicrobial agents - A composition comprising a macromer that can be in situ polymerized into a hydrogel wound dressing directly on a wound and one or more antimicrobial agents intended to achieve bacteriostasis and/or be bacteriocidal. The antimicrobial agent is released upon application and trapped in the hydrogel upon its formation and also released over a period of time into the wound. | 2012-01-12 |
20120009276 | COMPOSITION FOR THE TREATMENT OF OXIDATIVE STRESS - This invention is based on the observed oxidative stress and increased risk on cardiovascular diseases in subjects with increased lipid peroxidation, in particular with women using oral contraceptives and in hormone replacement therapies. The invention provides compositions and combinations, particularly useful in preventing and or reducing the increased lipid peroxidation in subjects in need thereof. These compositions are based on the synergistic combination of zinc and/or a hydroxyl radical scavenger in reducing lipid peroxidation. | 2012-01-12 |
20120009277 | METHOD FOR SELECTION OF NOVEL ANTI-CANCER HERBS USING CHEMINFORMATIC TOOLS - The various embodiments herein provide a new method of selecting novel anti-cancer herbs using cheminformatics tools. The method involves collecting the herbs having synergistic activity with anti-cancer compounds and categorizing the herbs as synergistic plants (SP). The bioactive compounds are selected from the SP and categorized into synergistic compounds collection (SCC). A similarity search is performed using the selected bioactive compounds through available databases to select similar compounds that are categorized as similar synergistic compounds (SSC). A herbal source for the SSC is searched and categorized as similar herbal synergistic compounds (SHSC). The novelty of the SHSC in cancer treatment is confirmed. The novel herbs are categorized as novel candidate herbs (NCH). The synergistic activity of the resulted herbs (NCH) is confirmed by performing in vitro bioassay. | 2012-01-12 |
20120009278 | Composition To Retard the Onset of Symptoms of Alzheimer's Disease - Compositions and methods are described for delaying the onset of the symptoms of Alzheimer's disease in humans. The compositions can include curcumin, piperine, oleic acid, oleanolic acid, ursolic acid, galantamine, and huperzine A, among other compounds. Curcumin is an antioxidant, while galantamine and huperzine A inhibit the activity of acetylcholinesterase in the brain. Piperine and oleic acid increase the bioavailability and gastrointestinal absorption of curcumin, galantamine, huperzine A, and other nutrients. The composition can also include at least one of phytic acid, piracetam, aniracetam, or indium. | 2012-01-12 |
20120009279 | METHOD OF TREATING A SUBSTRATE WITH STABLE BLEACHES WITH COLORING AGENTS - The invention provides an aqueous bleaching solution for substrate treatment comprising a source of oxidant and a suspended polymer matrix having a plurality of optically functional particles associated with one or more copolymers present in the polymer matrix. The plurality of optically functional particles are associated with the copolymer during polymerization of at least one hydrophobic and at least one hydrophilic monomer so as to form a polymer matrix useful to impart an aqueous bleaching solution with optically functional properties providing a benefit to the solutions during storage, use and application to substrates for treatment. In accordance with various embodiments of the invention, the suspended polymer matrix forms a substantially stable dispersion of the optically functional particles in the aqueous bleaching solution, and provides compositions, methods and kits for employing aqueous bleaching solutions having optically functional properties that are maintained over substantially long storage times. | 2012-01-12 |
20120009280 | METHOD OF REDUCING THE RATE OF DEGRADATION OF A BIOLOGICAL MATERIAL - A method of producing an animal feed product from a wet biological material, having a physical form selected from solutions, suspensions, emulsions, gums, mousses, sludges, slurries, and particulate materials, includes the step of combining the biological material with a base comprising a metal oxide in an amount which is sufficient to heat the biological material to a temperature of above 50° C. by reaction of water in the biological material with the metal oxide to produce the animal feed product. The product has a physical form which is easier to handle than that of the wet biological material and is selected from particulate materials and, granular materials. The base is preferably calcium oxide. | 2012-01-12 |
20120009281 | PLANT EXTRACTS FOR TREATING SKIN DISORDERS AND ENHANCING HEALING OF WOUNDS FOR DIABETIC PATIENTS - The present invention provides a pharmaceutical composition for treating skin disorders, including enhancing the healing of wounds for diabetic patients. Specifically, this invention relates to the use of the extracts of | 2012-01-12 |
20120009282 | USE OF THE COMBINATION OF PHY906 AND A TYROSINE KINASE INHIBITOR AS A CANCER TREATMENT REGIMEN - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of cancer by administering the herbal composition PHY906 in combination with one or more chemotherapeutic compounds to a mammal undergoing such chemotherapy. | 2012-01-12 |
20120009284 | ANTIMICROBIAL COMPOSITION AND METHOD FOR USING SAME - The compositions of the invention are comprised of three key elements: ethyl alcohol, essential oils, and water, which are mixed to provide a sprayable liquid that may be dispensed using a conventional pump spray or other appropriate dispenser. The major component is ethyl alcohol. The preferred essential oils are tea tree oil and peppermint oil. The composition is applied to a surface suspected of having harmful microbes thereon as a spray. | 2012-01-12 |
20120009285 | Compositions for treating skin - A personal care composition comprising: at least a first phase and a second phase wherein said first phase comprises a) an aqueous structured surfactant phase comprising STnS where n is between about 0 and about 2.5; b) ; c) a structuring system comprising i. optionally, a non-ionic emulsifier; ii. optionally, from about 0.05% to about 5%, by weight of said personal care composition, of an associative polymer; iii. an electrolyte; and said second phase comprises a) a benefit phase comprising from 1% to about 50%, by weight of said personal care composition, of a hydrophobic benefit agent. | 2012-01-12 |
20120009286 | WATER-SOLUBLE ANTIVIRAL PRODUCT CONTAINING MOMORDICA BALSAMINA, FOR THE TREATMENT AND PREVENTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND THE VARIANTS THEREOF - The invention relates to an antiviral product based on | 2012-01-12 |
20120009287 | METHOD AND HEATING DEVICE FOR THERMOFORMING - The present invention relates to a method of obtaining protein preparations from sunflower seeds as well as protein preparations produced with the method. In the method the sunflower seeds are dehulled to a residual hull content of 5% by weight or dehulled sunflower seeds with a residual hull content of 5% by weight are provided. Mechanical partial deoiling of the dehulled sunflower seeds is carried out through pressing up to a fat or oil content of the dehulled sunflower seeds in the range 10 to 35% by weight. After carrying out one or more extraction steps with at least one solvent, a defatted flour containing protein is obtained as a protein preparation. Both optically and functionally the protein preparation has very advantageous properties which allow it to be used directly in the food product or animal feed sector. | 2012-01-12 |
20120009288 | USE OF ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE - The present invention relates to a method for inhibition of xanthine oxidase comprising administrating an effective amount of the extracts from | 2012-01-12 |
20120009289 | WATER-SOLUBLE ANTIVIRAL PRODUCT CONTAINING CYPERUS ARTICULATUS, FOR THE TREATMENT AND PREVENTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND THE VARIANTS THEREOF - The invention relates to an antiviral product based on | 2012-01-12 |
20120009290 | Compositions for skin diseases or disorders - Medicaments or cosmetic compositions for the treatment or alleviation of skin or mucous membrane diseases or disorders related to an enhanced level of anti-microbial peptides or proteins comprising | 2012-01-12 |
20120009291 | DIE FOR UNDERWATER CUTTING TYPE PELLETIZER - A die for an underwater cutting type pelletizer, the die including a die orifice part in which a thermoplastic resin is inhibited from solidifying within the die orifices. The die can have a reduced difference in temperature between the die orifice part and an inner periphery-side fixing part for fixing the die orifice part to a mixer/extruder, and can thereby inhibit the generation of thermal stress. The die is characterized by being equipped with a heating jacket for heating the inner periphery-side fixing part, the heating jacket being disposed within the inner periphery-side fixing part along an inner annular passage formed within either the die orifice part or the inner periphery-side fixing part or both along the boundary between the die orifice part and the inner periphery-side fixing part. | 2012-01-12 |
20120009292 | METHOD AND APPARATUS FOR CONTROLLED ELECTROSPINNING - An electrospinning apparatus and methodology is described that produces medical devices, such as scaffolds that induce the formation of a natural fibrous structure (primarily collagen and elastin) in a tissue-engineered medical device. The apparatus uses collection surfaces designed to manipulate or change the electrostatic field so that the electrospun fibers are arranged in desirable patterns that are similar to or mimic the fibrillar structure of an animal tissue. The manipulation results in fibers that are preferentially oriented in a predefined pattern. In addition, the interfiber space between the fibers and the fiber diameter are consistently within a predefined range. Using these techniques in conjunction with controlling polymer properties enables the production of a scaffold that has the structural and mechanical characteristics similar to the native tissue. | 2012-01-12 |
20120009293 | MOLDING MACHINE AND METHOD FOR FORMING OPTICAL FILM - A molding machine for manufacturing an optical film includes a hopper, a first cylindrical roller, a second cylindrical roller, and an ultraviolet light source. The hopper defines a narrow outlet. The first cylindrical roller is rotatable around its central axis parallel to the narrow outlet. The second cylindrical roller is a transparent hollow structure rotatable around its second central axis. The first central axis is parallel to the second central axis at the same level. The first and second cylindrical rollers are located at two opposite sides of the narrow outlet and below the narrow outlet, and define a gap therebetween to feed the raw material. The ultraviolet light source is located in the second cylindrical roller. An emission direction of the ultraviolet light source is orientated toward a space between the narrow outlet and the second cylindrical roller. | 2012-01-12 |
20120009294 | METHOD AND APPARATUS FOR STRETCHING AND CRYSTALLIZING THE NECK FINISH OF A MOLDED PLASTIC ARTICLE - Apparatus and method for making a molded plastic article having a stretched and crystallized neck finish. In one embodiment, a series of platforms are carried by a conveying apparatus for transporting a series of molded plastic articles along a predetermined path of travel through one or more treatment stations. At a finish widening station, the molded article, having a relatively wide and thin-walled blow-molded body portion, and a relatively narrow and thick-walled unexpanded neck finish portion, is positioned to enable insertion of a mandrel into an open top aperture of the finish portion to widen the finish. | 2012-01-12 |
20120009295 | DEVICE FOR STRETCHING AN ELASTIC RING - A device for stretching a plastic ring which comprises pushing means ( | 2012-01-12 |
20120009296 | LIGHT GUIDE PLATE MOLD - A light guide plate mold is configured for manufacturing a light guide plate having a number of microstructures. The light guide plate mold includes a substrate and a number of heating members. The substrate defines a number of grooves therein. The heating members are respectively received in the grooves. Each heating member has a height less than a depth of the corresponding groove. The grooves and the heating members cooperatively define a number of receiving spaces for forming the microstructures of the light guide plate. | 2012-01-12 |
20120009297 | ELECTROMOTIVE INJECTION MOLDING MACHINE AND POWER SUPPLYING METHOD OF ELECTROMOTIVE INJECTION MOLDING MACHINE - To provide a power supplying method that can reduce the maximum power of an electromotive injection molding machine including a power supplying apparatus having a predetermined power storage circuit. | 2012-01-12 |
20120009298 | METHOD FOR PRODUCING NOODLE, AND ENZYME PREPARATION FOR MODIFYING NOODLE - A noodle having improved physical properties and improved taste may be obtained with an enzyme preparation for modifying a noodle, which contains α-glucosidase and glucose oxidase. | 2012-01-12 |